Connect Biopharma Holdings reported a net margin of -624.42% for the quarter ended Jun 2026. These financial ratios cover 15 quarters of results from Dec 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2021 | Jun2022 | Dec2022 | Jun2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||
| EBT Margin | -1,051.60% | -1,260.74% | -26,758.33% | -107,118.75% | -11,449.70% | -622.25% | |||||||||
| EBIT Margin | -1,135.85% | -1,378.08% | -27,966.67% | -110,481.25% | -11,601.78% | -635.98% | |||||||||
| EBITDA Margin | -1,135.85% | -1,378.08% | -27,966.67% | -110,481.25% | -11,601.78% | -635.98% | |||||||||
| Operating Margin | -1,135.85% | -1,378.08% | -27,966.67% | -110,481.25% | -11,601.78% | -635.98% | |||||||||
| Net Margin | -1,056.28% | -1,275.93% | -26,872.92% | -107,500.00% | -11,478.11% | -624.42% | |||||||||
| FCF Margin | -1,079.08% | -377.08% | -26,862.50% | -109,000.00% | -9,469.23% | -575.18% | |||||||||
| Efficiency | |||||||||||||||
| Assets AverageAssets Avg. | 226.97M | 262.47M | 202.55M | 157.24M | 135.73M | 96.98M | 87.70M | 75.04M | 61.72M | 58.07M | 51.77M | ||||
| Asset Utilization RatioAsset Util. | 0.02 | 0.01 | 0.00 | 0.00 | 0.06 | ||||||||||
| Valuation | |||||||||||||||
| Price to EarningsP/E | -11.01 | 5.66 | -6.18 | -8.58 | -2.96 | -4.22 | -4.90 | -10.53 | -8.47 | -8.67 | |||||
| Price to SalesP/S | 65.27 | 109.43 | 0.00M | 0.01M | 972.22 | 54.15 | |||||||||
| Price to BookP/B | 1.04 | 0.22 | 0.31 | 0.48 | 0.64 | 1.02 | 0.76 | 0.79 | 0.83 | 0.37 | 0.76 | 1.52 | 3.79 | 3.85 | 5.58 |
| Enterprise Value | 16.67M | -146.11M | -101.37M | -73.54M | -53.28M | 95.72M | -26.21M | 79.57M | -17.35M | -53.57M | -17.30M | 29.46M | 114.82M | 118.27M | 118.36M |
| EV to EBIT | -7.58 | -1.92 | -5.75 | 1.80 | 4.68 | 1.29 | -1.67 | -7.40 | -6.03 | -6.72 | |||||
| EV to EBITDA | -7.58 | -1.92 | -5.75 | 1.80 | 4.68 | 1.29 | -1.67 | -7.40 | -6.03 | -6.72 | |||||
| Market Capitalization | 283.64M | 47.92M | 47.89M | 62.20M | 65.02M | 95.72M | 83.99M | 79.57M | 76.38M | 30.44M | 54.47M | 84.24M | 159.17M | 164.30M | 149.88M |
| Price to FCFP/FCF | -161.69 | -10.52 | -6.05 | -29.02 | -3.03 | -4.22 | -4.83 | -13.92 | -10.27 | -9.41 | |||||
| EV to FCF | -161.69 | 3.28 | -6.05 | 6.59 | 5.34 | 1.34 | -1.69 | -10.04 | -7.39 | -7.43 | |||||
| EV to CFO | -161.97 | 3.41 | -6.12 | 7.48 | 5.38 | 1.37 | -1.69 | -10.21 | -7.39 | -7.43 | |||||
| Return Ratios | |||||||||||||||
| Return on Sales [ROS]ROS | -1,135.85% | -1,378.08% | -27,966.67% | -110,481.25% | -90,740.63% | -11,601.78% | -635.98% | ||||||||
| Return on Capital Employed [ROCE]ROCE | -24.05% | -62.80% | -82.00% | -120.72% | -161.45% | -198.53% | |||||||||
| Return on Assets [ROA]ROA | -17.74% | -51.25% | -65.67% | -89.89% | -111.25% | -133.27% |